All In Biotech

Drug Trial Radar · NCT03955211

PK and Safety After C-Section

A Phase 2, Open-Label Study of the Pharmacokinetics and Safety of HTX-011 Administered Postpartum to Women Undergoing a Planned Caesarean Section

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Jun 24, 2019

Primary completion

Dec 3, 2021

Study completion Dec 27, 2021

Sponsor

Lead sponsor
Heron TherapeuticsIndustry
Sponsor type
Industry
First posted
May 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of the study was to measure the amount of the active ingredients and other components of HTX-011 in plasma and expressed breast milk over time following postpartum administration in women undergoing a planned C-section. The study also looked at the safety of HTX-011 in these women.

Conditions

  • Postoperative Pain

Interventions

  • HTX-011Drug

    bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

  • ZYNRELEF kit components for administrationDevice

    ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

  • MMA regimenDrug

    PO ibuprofen 400 mg every 6 hours (q6h), alternating with PO acetaminophen 975 mg to 1 g q6h, alternating the 2 medications so that an analgesic was taken approximately every 3 hours (q3h) while the subject was awake

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bupivacaine Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  2. Bupivacaine Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  3. Bupivacaine Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  4. Bupivacaine Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  5. Bupivacaine Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  6. Bupivacaine Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  7. Bupivacaine Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  8. Meloxicam Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  9. Meloxicam Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  10. Meloxicam Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  11. Meloxicam Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  12. Meloxicam Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  13. Meloxicam Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  14. Meloxicam Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Helen Keller Hospital

    Sheffield, Alabama

  • Sharp Mary Birch Hospital for Women and Newborns

    San Diego, California

  • Duke University Medical Center

    Durham, North Carolina

  • UPMC Magee-Womens Hospital

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.